topic

1017 SLAMF7+ CD8+ exhausted T cell-specific gene signature is associated with resistance to PD1 blockade in renal cell carcinoma
Miya Hugaboom, Kelly Street, Neil Ruthen, Lena Wirth, Opeyemi A Jegede, Nicholas Schindler, David F McDermott, Elizabeth Plimack, Jeffrey Sosman, Naomi B Haas, Michael Hurwitz, Hans Hammers, Sabina Signoretti, Michael B Atkins, Catherine J Wu, David Braun

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1125; DOI: 10.1136/jitc-2023-SITC2023.1017
1018 A transcriptional signature shared by circulating cancer-specific CD8 T cells
Saumya Jani, Thomas Pulliam, Nandita Kumar, Ana Jojic, Rashmi Bhakuni, Evan Newell, Paul Nghiem

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1126; DOI: 10.1136/jitc-2023-SITC2023.1018
1019 Dysfunctional mitochondria promotes T cell exhaustion and DNA damage responses in CD8⁺ T cells
Kung-Chi Kao, Yi-Ru Yu, Ping-Chih Ho

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1127; DOI: 10.1136/jitc-2023-SITC2023.1019
1020 Proteomic analysis of T cell exhaustion unveils differential modulation of the DNA damage response
Jessica L Kelliher, Daniel Fil, Latambria Hampton, Lora J Rogers, Sydnye L Shuttleworth, Brian Koss

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1128; DOI: 10.1136/jitc-2023-SITC2023.1020
1021 A platform to assess prevention and reversal of T cell exhaustion caused by persistent T cell stimulation
Elsenoor Klaver, Paulina Goral, Tetiana Herheliuk, Lauren Kelsey, Marie Carkill, Robert Nunan, Louise Brackenbury

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1129; DOI: 10.1136/jitc-2023-SITC2023.1021
1022 Sex-biased T cell exhaustion drives differential immune responses in glioblastoma
Juyeun Lee, Michael Nicosia, Ellen Hong, Daniel Silver, Cathy Li, Justin Lathia

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1130; DOI: 10.1136/jitc-2023-SITC2023.1022
1023 Cell-intrinsic Tim-3 is required for optimal CD8 response to acute LCMV infection
Priyanka Manandhar, Emily Landy, Lawrence Kane

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1131; DOI: 10.1136/jitc-2023-SITC2023.1023
1024 CLN-978, a novel CD19/CD3/HSA T cell engager with extended serum half-life, is effective against lymphoma cells expressing very low levels of CD19
Kristan A Meetze, Naveen K Mehta, Jennifer S Michaelson, Patrick A Baeuerle, Hannah M Findlay, Timothy B London, Agapitos Patakas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1132; DOI: 10.1136/jitc-2023-SITC2023.1024
1025 Tumor-specific CD8+ T cells epigenetically licensed by IL-7R are critical for anti-tumor immunity in melanoma
Goran Micevic, Andrew Daniels, Karine Flem-Karlsen, Koonam Park, Ronan Talty, Meaghan McGeary, Haris Mirza, Holly N Blackburn, Esen Sefik, Julie F Cheung, Noah Hornick, Lilach Aizenbud, Nikhil Joshi, Harriet Kluger, Akiko Iwasaki, Marcus Bosenberg, Richard Flavell

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1133; DOI: 10.1136/jitc-2023-SITC2023.1025
1026 PIK3IP1/TrIP immune regulation on CD8⁺ T cells restricts anti-tumor immunity
Benjamin M Murter, Hridesh Banerjee, Sean Robinson, Andrea L Szymczak-Workman, Lawrence P Kane

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A1134; DOI: 10.1136/jitc-2023-SITC2023.1026

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages